Phreesia (PHR) Stock Forecast & Price Target

$18.53 -0.02 (-0.11%)

(As of 11/20/2024 ET)

Phreesia - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
1

Buy
11

Based on 12 Wall Street analysts who have issued ratings for Phreesia in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a hold rating, and 11 have given a buy rating for PHR.

Consensus Price Target

$29.42
58.75% Upside

According to the 12 analysts' twelve-month price targets for Phreesia, the average price target is $29.42. The highest price target for PHR is $34.00, while the lowest price target for PHR is $23.00. The average price target represents a forecasted upside of 58.75% from the current price of $18.53.

Get the Latest News and Ratings for PHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Phreesia and its competitors.

PHR Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$29.42	$29.42	$30.54	$37.15
Forecasted Upside	58.75% Upside	50.09% Upside	20.28% Upside	138.17% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

PHR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Phreesia Stock vs. The Competition

Type	Phreesia	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	58.75% Upside	26,931.54% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent PHR News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/27/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Sector Perform ➝ Sector Perform	$23.00 ➝ $23.00	+2.09%
9/9/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$27.00 ➝ $28.00	+17.60%
9/6/2024	Truist Financial 2 of 5 stars		Boost Target	Buy ➝ Buy	$29.00 ➝ $31.00	+22.29%
9/6/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$31.00 ➝ $34.00	+32.35%
9/5/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$30.00 ➝ $30.00	+26.10%
9/5/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$34.00 ➝ $34.00	+44.07%
Get the Latest News and Ratings for PHR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter.
9/5/2024	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Jellison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00	+33.78%
9/5/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00	+19.98%
7/11/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$27.00 ➝ $25.00	+32.77%
5/31/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$28.00 ➝ $28.00	+52.76%
3/15/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$25.00 ➝ $30.00	+32.45%
1/3/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$29.00	+26.36%
9/12/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$43.00 ➝ $40.00	+82.98%
9/7/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
9/7/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$40.00 ➝ $37.00	+21.87%
3/29/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$35.00 ➝ $40.00	+28.66%
1/5/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$34.00 ➝ $39.00	+23.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:09 AM ET.

PHR Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Phreesia is $29.42, with a high forecast of $34.00 and a low forecast of $23.00.
: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There is currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PHR shares.
: According to analysts, Phreesia's stock has a predicted upside of 58.75% based on their 12-month stock forecasts.
: Phreesia has been rated by research analysts at Canaccord Genuity Group, DA Davidson, JMP Securities, JPMorgan Chase & Co., Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, and Truist Financial in the past 90 days.
: Analysts like Phreesia more than other "medical" companies. The consensus rating score for Phreesia is 2.92 while the average consensus rating score for "medical" companies is 2.80. Learn more on how PHR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

This page (NYSE:PHR) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phreesia (PHR) Stock Forecast & Price Target